Abstract: This invention relates to a highly functional graft copolymer and a method of preparing the same, and more particularly, to a highly functional graft copolymer including a main chain of a highly elastic ethylene-based terpolymer including, at a predetermined molar ratio, an ethylene unit, an ?-olefin unit having 6 to 12 carbon atoms, and at least one functional unit selected from the group consisting of divinylbenzene and p-methylstyrene, and a side chain of a polar polymer for imparting functionality, and to a method of preparing the highly functional graft copolymer by performing anionic polymerization after catalytic polymerization using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to an ethylene-based terpolymer having high elasticity and a preparation method thereof, and more particularly, to a highly elastic, ethylene-based terpolymer, which comprises a specific molar ratio of a ethylene unit, a C6-12 ?-olefin unit and at least one functional unit selected from the group consisting of divinylbenzene and para-methylstyrene and to a method of preparing the highly elastic, ethylene-based terpolymer using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Abstract: The present invention relates to a self-adhesive protection film having improved release properties and a product attached with the same, and in particular, to a multilayered self-adhesive protection film having particularly enhanced release properties by comprising monodisperse beads in a carrier layer or the carrier layer being embo patterned, and to a product attached with the self-adhesive protection film.

Abstract: This invention relates to a highly functional graft copolymer and a method of preparing the same, and more particularly, to a highly functional graft copolymer including a main chain of a highly elastic ethylene-based terpolymer including, at a predetermined molar ratio, an ethylene unit, an ?-olefin unit having 6 to 12 carbon atoms, and at least one functional unit selected from the group consisting of divinylbenzene and p-methylstyrene, and a side chain of a polar polymer for imparting functionality, and to a method of preparing the highly functional graft copolymer by performing anionic polymerization after catalytic polymerization using a metallocene catalyst.

Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.